Trials / Active Not Recruiting
Active Not RecruitingNCT06764771
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 437 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986488 | Specified dose on specified days |
| DRUG | Adagrasib | Specified dose on specified days |
| DRUG | Cetuximab | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2025-03-25
- Primary completion
- 2027-10-15
- Completion
- 2027-10-15
- First posted
- 2025-01-08
- Last updated
- 2025-12-17
Locations
7 sites across 3 countries: United States, Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06764771. Inclusion in this directory is not an endorsement.